American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · Nov 2012
Randomized Controlled TrialReversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study.
Reversal of sepsis-induced immunoparalysis may reduce the incidence of secondary infections and improve outcome. Although IFN-γ and granulocyte-macrophage colony-stimulating factor (GM-CSF) restore immune competence of ex vivo stimulated leukocytes of patients with sepsis, effects on immunoparalysis in vivo are not known. ⋯ IFN-γ partially reverses immunoparalysis in vivo in humans. These results suggest that IFN-γ is a promising treatment option to reverse sepsis-induced immunoparalysis.